These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27993814)

  • 1. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
    Gyawali B; Ando Y
    Ann Oncol; 2017 Apr; 28(4):898-899. PubMed ID: 27993814
    [No Abstract]   [Full Text] [Related]  

  • 2. Sunitinib as adjuvant therapy for renal cell carcinoma.
    Baker H
    Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
    Teo M; Downey FP; McDermott RS
    Clin Genitourin Cancer; 2013 Jun; 11(2):198-200. PubMed ID: 23276590
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
    Nicholaou T; Wong R; Davis ID
    Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
    Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.
    Ueda K; Noguchi M; Suekane S; Moriya F; Nagayoshi R; Ejima K; Momozono K; Matsuoka K
    Kurume Med J; 2011; 58(3):95-8. PubMed ID: 22531125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma.
    Van Keerberghen CA; Jean-Baptiste J; Wolter P; Zucman-Rossi J; Schöffski P; Beuselinck B
    Clin Genitourin Cancer; 2015 Dec; 13(6):e407-10. PubMed ID: 26026260
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.
    Reddy K
    Clin Genitourin Cancer; 2006 Jun; 5(1):23-5. PubMed ID: 16859575
    [No Abstract]   [Full Text] [Related]  

  • 12. Mixed Results for Sunitinib in Renal Cancer.
    Cancer Discov; 2017 Jan; 7(1):OF6. PubMed ID: 28062674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.
    Thibault F; Billemont B; Rixe O
    J Neurooncol; 2008 Jan; 86(2):243-4. PubMed ID: 17634858
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.
    Daste A; Gross-Goupil M; Quivy A; François L; Bernhard JC; Ravaud A
    Clin Genitourin Cancer; 2016 Oct; 14(5):e525-e527. PubMed ID: 27185091
    [No Abstract]   [Full Text] [Related]  

  • 15. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.
    Bex A; Albiges L; Ljungberg B; Bensalah K; Dabestani S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Lam TB; Marconi L; Merseburger AS; Staehler M; Volpe A; Powles T
    Eur Urol; 2017 May; 71(5):719-722. PubMed ID: 27986369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
    Bex A; Van der Veldt AA; Blank C; Meijerink MR; Boven E; Haanen JB
    Acta Oncol; 2010 May; 49(4):520-3. PubMed ID: 20105087
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of locally advanced renal tumors].
    Sánchez Zalabardo D; Millán Serrano JA; De Pablo Cárdenas A; Cuesta Alcalá JA
    Actas Urol Esp; 2010 Feb; 34(2):134-41. PubMed ID: 20403277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib in renal-cell carcinoma: expanded indications.
    Choueiri TK; Bellmunt J
    Lancet Oncol; 2009 Aug; 10(8):740. PubMed ID: 19615941
    [No Abstract]   [Full Text] [Related]  

  • 20. New challenges in kidney cancer therapy: sunitinib.
    Izzedine H; Billemont B; Thibault F; Rixe O
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix83-6. PubMed ID: 17631600
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.